MentalHealthDaily

Alpha-Synuclein SAA Predicts Parkinson’s Levodopa Response Durability

by GLOOM

Photoreal illustration of CSF biomarker testing alongside dopaminergic neuron pathways, representing PD biomarker stratification.

A 2026 PPMI analysis found that Parkinson’s patients with positive CSF α-synuclein seed amplification assay results kept gaining levodopa benefit over follow-up, while SAA-negative patients showed faster ON-medication motor progression than SAA-positive patients: 0.87 vs. 3.47 MDS-UPDRS Part III points/year in 183 matched SAA-positive and 40 SAA-negative patients.1 Research Highlights ON-state progression split sharply: SAA-positive …

Parkinson’s Disease Prevention: Prodromal Symptoms, RBD, Early Intervention Trials

by GLOOM

Photoreal illustration of a brain with prodromal pathology and a clock indicating early-window intervention opportunity for Parkinson's prevention.

Parkinson’s disease has a years-to-decades prodromal stage where motor symptoms haven’t yet emerged but pathology is accumulating. A 2026 review by Schaeffer et al. synthesizes the case for (and limits of) intervening during this window — with implications for high-risk individuals weighing whether to enter preventive trials.1 Research Highlights Prodromal Parkinson’s disease is the period …

Ubiquinol for Multiple System Atrophy: First Positive Repurposing Trial

by GLOOM

Photoreal illustration of misfolded alpha-synuclein in glial cells with drug molecule motifs, representing repurposed-drug therapeutics in MSA.

Multiple system atrophy is a rapidly progressive neurodegenerative disease with no proven disease-modifying therapy. A 2026 review by Jeong and colleagues tracks two decades of repurposed-drug trials, with one recent positive Phase 2 result.1 Research Highlights Multiple system atrophy (MSA) is a fatal α-synuclein disorder distinct from Parkinson’s disease. It progresses faster than PD (median …